Percutaneous absorption enhancers: mechanisms and potential

Transdermal applications of drugs present many advantages in terms of absorption, however this is not easily obtained through the transdermal route. The principle barrier is the stratum corneum and one of the strategies that have been found to promote cutaneous drug penetration is through the use of absorption enhancers. Many substances have been identified as absorption enhancers. Although the list of substances that promote absorption is growing, in most cases, there is a direct correlation between the effects of absorption enhancers and their skin toxicity. The use of these substances depends therefore on studies which focus on local and systemic toxicity, as well as action mechanisms.<br>A via transdérmica para a absorção de fármacos apresenta várias vantagens, porém a absorção através desta via não é fácil de ser obtida. A principal barreira encontrada é o estrato córneo e uma das estratégias encontradas para promover a permeação cutânea de fármacos é o uso de promotores de absorção. Há uma variedade de substâncias identificadas como promotores de absorção. Enquanto a lista de substâncias de promotores de absorção percutânea vem aumentando, na maioria dos casos, há uma correlação entre o efeito promotor e a toxicidade para a pele. O emprego destas substâncias depende, portanto, de estudos enfocando a toxicidade local e sistêmica, bem como o mecanismo de ação

Vehicle effects on the in vitro penetration of testosterone through equine skin

The effects of three vehicles, phosphate-buffered saline (PBS), ethanol (50% in PBS w/w) and propylene glycol (50% in PBS w/w) on in vitro transdermal penetration of testosterone was investigated in the horse. Skin was harvested from the thorax of five Thoroughbred horses after euthanasia and stored at -20 degrees C until required. The skin was then defrosted and placed into Franz-type diffusion cells, which were maintained at approximately 32 degrees C by a water bath. Saturated solutions of testosterone, containing trace amounts of radiolabelled [C-14]testosterone, in each vehicle were applied to the outer (stratum corneum) surface of each skin sample and aliquots of receptor fluid were collected at 0, 2, 4, 8, 16, 20, 22 and 24 h and analysed for testosterone by scintillation counting. The maximum flux (J(max)) of testosterone was significantly higher for all sites when testosterone was dissolved in a vehicle containing 50% ethanol or 50% propylene glycol, compared to PBS. In contrast, higher residues of testosterone were found remaining within the skin when PBS was used as a vehicle. This study shows that variability in clinical response to testosterone could be expected with formulation design